Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

Zhan, Ping; Wang, Jing; Lv, Xiao; Wang, Qin; Qiu, Li Xin; Lin, Xin; Liu, Yu; Song, Yong

doi:10.1097/jto.0b013e3181a97e31

Cited by 179 publications

(119 citation statements)

References 72 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Tumor growth and metastasis require angiogenesis, which is regulated by various factors, including the vascular endothelial growth factor (VEGF) (17). VEGF overexpression is an indicator of poor prognosis in patients with non-small and small cell lung cancer (18). Shimanuki et al measured the serum VEGF levels preoperatively in patients with non-small cell lung cancer and revealed a correlation with microvessel density in the resected tumor.…”

Section: Introductionmentioning

confidence: 99%

Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

et al. 2011

View full text Add to dashboard Cite

Abstract. Vascular endothelial growth factor-A (VEGF-A)affects tumor growth and metastasis through stimulation of angiogenesis. The purpose of this study was to describe features of Lewis lung cancer (LLC) in mice and compare the serum VEGF-A levels with those of normal control mice. Two groups of mice were compared: one was subcutaneously injected with LLC cells (n=16) and the other served as the normal control (n=6). The serum VEGF-A levels were measured by ELISA prior to inoculation, and at 7, 21 and 35 days post-inoculation. The tumor weight and the metastatic condition were evaluated on day 35. Changes in body weight and serum VEGF-A concentration over a period of time were compared between the groups using generalized estimating equations. The relationship between the primary tumor and the metastatic condition was analyzed using the Spearman's rank correlation test. The survival rate was 56.3% on day 35 post-tumor inoculation. No difference was found between the groups with regard to gastrocnemius muscle weight on day 35 post-inoculation [0.1315±0.0066 g vs. 0.1308±0.0069 g (normal control)]. In tumor-bearing mice, the weight gain at sacrifice was less (0.24±0.45 vs. 1.93±0.47 g, P= 0.01), the final mean tumor volume and weight were 4264.69±1038.32 mm 3 and 3.70±0.83 g, the number of nodules in the lungs and livers was 6.33 (range 0-20) and 2.22 (range 0-11), respectively, and the serum VEGF-A levels were significantly higher than those of control mice. In conclusion, lower body weight gain, metastasis in the liver and lungs, and elevated VEGF-A levels are features of LLC in mice.

show abstract

Section: Introductionmentioning

confidence: 99%

Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Confirming these results, in the previously mentioned study by Lucchi et al, VEGF levels were an independent adverse prognostic factor in the adjuvant setting (25). Additionally, Zhan et al performed a systematic review and meta-analysis of VEGF expression in lung cancer and again confirmed that VEGF is a prognostic factor in SCLC (32). Moreover, it has been demonstrated that SCLC cell lines express VEGFR2/3 receptors suggesting that the VEGF/VEGFR pathway is an autocrine growth regulator in SCLC (33).…”

Section: Angiogenesis In Sclcmentioning

confidence: 55%

Targeting angiogenesis in small cell lung cancer

Stratigos

Matikas

Voutsina

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is a highly aggressive and lethal malignancy. Despite high initial response rates to systemic chemotherapy, the disease eventually relapses; further treatment only modestly improves outcomes and overall survival (OS) for patients with extensive stage disease is less than one year.Little progress has been made during the past decades, with no new drugs approved. Consequently, the development of novel strategies is an unmet need. The inhibition of angiogenesis, a defining characteristic of cancer, has demonstrated modest efficacy in several human malignancies, including non-small cell lung cancer (NSCLC). However, results from clinical trials in SCLC have been disappointing, and no anti-angiogenic agent has received regulatory approval due to lack of clinical efficacy. The elucidation of underlying mechanisms responsible for tumor resistance to angiogenic therapy and the simultaneous blockade of multiple elements that play a role in angiogenesis need to be further explored.

show abstract

“…In a recent meta-analysis of 5,386 NSCLC and SCLC patients, VEGF overexpression indicated poor survival for those with NSCLC histology, whereas VEGFR-3 expression did not affect prognosis (17).…”

Section: Discussionmentioning

confidence: 99%

“…There is plentiful literature regarding the association of angiogenic factors with disease prognosis (4,(14)(15)(16)(17)(18)(19)(20); however, only a few studies evaluate the role of such factors in predicting response to chemotherapy (21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients

Koufos

Syrios

Michailidou

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. Freshly isolated lung tumour specimens obtained by bronchoscopy from 70 stage IIIA NSCLC chemotherapy-naïve patients were sampled and analysed for vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3. Microvessel density was assessed through evaluating the angiogenic markers CD34 and CD105.

show abstract

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

Abstract: VEGF overexpression indicates a poor prognosis for patients with NSCLC and SCLC; VEGFC and VEGFR3/flt-1 overexpression was not significantly correlated with survival for patients with NSCLC.

Cited by 179 publications

References 72 publications

Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer

Targeting angiogenesis in small cell lung cancer

Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients

Contact Info

Product

Resources

About